// App-Quantinova.ai

502 : Reduction in Disease Activity in Patients with RA and an Inadequate Response to MTX: Baricitinib Compared to Adalimumab and Placebo

Researchers

Presenter

  • Peter Nash

Principal Investigators

  • Janet E. Pope

  • Anabela Cardoso

  • Marta Casillas

  • Douglas E. Schlichting

  • Baojin Zhu

  • Scott D. Beattie

  • Josef S. Smolen

Medical Centers

  • The University of Queensland, Brisbane, Australia

  • St Josephs Health Care, London, Canada

  • Eli Lilly and Company, Indianapolis, IN

  • Hepatology AKH, Medical University of Vienna, Vienna, Austria

Locations

  • Australia

  • Canada

  • United States

  • Austria

Companies

  • Eli Lilly and Compan

Study Components

Therapeutic Area

  • N/A

Disease

  • N/A

Biomarkers

  • N/A

Drug/Treatment

  • Baricitinib

  • Adalimumab

  • BARI

Outcome

  • N/A

Study Design

  • Placebo Control

Phase

  • III

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved